Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 331

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 331
---
 $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish the public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of Iris’s remaining stockholders and the Iris Board, liquidate and dissolve, subject, in each case, to Iris’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

#### Redemption Rights
In connection with the Business Combination, our stockholders will be entitled to redeem all or a portion of their public shares for a pro rata share of the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the Business Combination, including interest earned on the funds held in the Trust Account (which interest shall be net of all applicable taxes payable from the Trust Account), divided by the number of then outstanding public shares, subject to the limitations and on the conditions described herein. See “ Special Meeting of Iris Stockholders — Redemption Rights and Procedures ” for a description of redemption procedures.

The Sponsor, officers and directors have agreed to: (i) waive their redemption rights with respect to any Founder Shares and public shares they hold in connection with the completion of the initial business combination, (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a stockholder vote to approve an amendment to the Iris Certificate of Incorporation, (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if Iris fails to complete the initial business combination within required time period, and (iv) vote any Founder Shares held by them and any public shares purchased during or after the IPO in favor of the initial business combination.

### Background on our Sponsor
Our Sponsor, Iris Acquisition Holdings LLC, is owned by: (i) a private equity fund managed by Arrow Capital (“Arrow”) and (ii) Iris Equity Holdings LLC, a Delaware limited liability company. Iris Equity Holdings LLC is the managing member of our Sponsor.

Arrow is a leading boutique asset manager and investment advisory firm. Iris Equity Holdings LLC is a vehicle formed and owned by Gaius Investment Partners Co., Ltd., a Korean company.

<div align='center'>174</div>

TABLE OF CONTENTS

#### Employees and Human Capital Resources
We have three executive officers. These individuals are not obligated to